Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 1/20 | 0.41 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.41 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.41 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.41 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.41 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.41 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.41 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.41 |
| ▸ | ATP12A | P54707 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SOD1 | P00441 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714764 | 1.00 | ATP1A1 (0.41) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL1650207 | 1.00 | ATP1A1 (0.41) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL309087 | 1.00 | ATP1A1 (0.41) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL31237867 | 0.82 | ATP1A1 (0.47) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL27886000 | 0.75 | ATP1A1 (0.45) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL3134704 | 0.73 | ATP12A (0.69) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL4148208 | 0.71 | ATP1A1 (0.73) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL6857605 | 0.71 | ATP1A1 (0.73) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL30505265 | 0.71 | ATP1A1 (0.73) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL6857608 | 0.71 | ATP1A1 (0.73) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4581143-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | University of Rochester (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250066790-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODIFYING PROTEIN EXPRESSION | UNIVERSITY OF ROCHESTER | 2025-02-27 | — | — | US | disclosed |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF ROCHESTER | 2025-01-16 | — | — | US | disclosed |
| US-20250018009-A1 | SERUM RESPONSE FACTOR REGENERATES SENESCENT CELLS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-01-16 | — | — | US | disclosed |
| CN-1143318-A | Transdermal device containing polyvinylpyrrolidone as dissolution enhancer | NOVEN PHARMA (US) | 1997-02-19 | — | — | CN | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0051964-A2 | Animal growth control | Naylor, Graham John (GB) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | ATP1A1 1500/4885ATP1B1 2790/4885ATP1A3 1279/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | ATP1A1 1394/4885ATP1B1 1587/4885ATP1A3 2394/4885 |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UPF1, TNNI3, TNNT2 | ATP1A1 1033/4885ATP1B1 1740/4885ATP1A3 993/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | ATP1A1 194/4885ATP1B1 226/4885ATP1A3 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.